Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI

Executive Summary

Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said

You may also be interested in...



OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement

OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent

OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement

OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent

OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan

OSI Pharmaceuticals is confident about Tarceva's prospects for FDA clearance based on the recent Subpart H approval of AstraZeneca's Iressa

Related Content

UsernamePublicRestriction

Register

PS040583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel